Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa
Examines reinfection as a major biological constraint on TB vaccine effectiveness. The article evaluates how repeated exposure to M. tuberculosis can increase bacterial burden and reduce the additional protection provided by vaccination.
Project details
Country
Timeline
Target group
Type of protection of vaccine
Type of research
Partners involved
Africa Health Research Institute, civil society and community representatives, Gates Foundation, manufacturers, policymakers, regulators, South African National Department of Health, South African Tuberculosis Vaccine Initiative (SATVI), TB Proof, The Aurum Institute, University of Cape Town, University of the Witwatersrand, World Health Organization